Table IV.
Association between gene expression and clinical characteristics.
| Genes mRNA expression levels (mean ± standard error)a | ||||||||
|---|---|---|---|---|---|---|---|---|
| Clinical values | ERCC1 | BRCA1 | TUBB3 | FBW7 | RRM1 | MDM2 | TS | TOP1 |
| Sex | ||||||||
| Male | 4.4±0.5 | 1.1±0.1 | 1.0±0.2 | 5.0±0.9 | 1.7±0.2 | 5.5±0.9 | 1.7±0.4 | 3.4±0.9 |
| Female | 5.2±1.0 | 1.4±0.3 | 1.3±0.4 | 9.0±3.8 | 1.9±0.5 | 7.1±1.4 | 1.2±0.2 | 4.0±0.8 |
| Age | ||||||||
| ≤62 | 4.5±0.6 | 1.0±0.1 | 0.7±0.1 | 7.0±2.6 | 1.7±0.2 | 5.2±0.9 | 1.5±0.4 | 3.6±1.0 |
| >62 | 4.2±0.8 | 1.5±0.3 | 1.5±0.4 | 5.9±1.0 | 1.9±0.4 | 7.2±1.3 | 1.6±0.3 | 3.7±0.7 |
| Tumor site | ||||||||
| Upper | 3.5±0.4 | 1.0±0.2 | 0.6±0.3 | 2.6±1.7 | 1.8±0.5 | 4.0±1.6 | 2.6±1.7 | 1.9±0.7 |
| Middle | 5.3±0.7 | 1.4±0.2 | 1.2±0.3 | 8.0±2.5 | 2.0±0.3 | 7.4±1.1 | 1.6±0.3 | 4.3±1.0 |
| Lower | 4.0±0.8 | 1.0±0.1 | 0.9±0.3 | 4.9±0.8 | 1.4±0.3 | 4.2±0.9 | 1.1±0.3 | 2.9±0.6 |
| Histological grade | ||||||||
| 1 | 4.8±1.4 | 1.2±0.2 | 0.8±0.3 | 4.4±1.1 | 1.3±0.3 | 4.4±1.1 | 1.3±1.1 | 3.4±1.3 |
| 2 | 4.7±0.5 | 1.2±0.2 | 1.1±1.2 | 7.0±1.9 | 1.9±0.3 | 6.5±0.9 | 1.6±0.3 | 3.7±0.7 |
| Stage | ||||||||
| II | 5.1±0.7 | 1.3±0.2 | 1.1±0.3 | 6.1±1.1 | 1.9±0.3 | 7.2±1.2 | 1.5±0.2 | 4.1±1.0 |
| III | 4.2±0.7 | 1.1±0.1 | 1.0±0.3 | 7.0±3.1 | 1.6±0.2 | 4.7±0.9 | 1.6±0.5 | 3.1±0.6 |
a
All P>0.05. ERCC1, excision repair cross-complementation group 1; BRCA1, breast cancer type 1 gene; TUBB3, tubulin β-3 class III; FBXW7, F-box and WD repeat domain containing 7; RRM1, ribonucleotide reductase catalytic subunit M1; MDM2, murine double minute 2; TS, thymidylate synthetase; TOP1, DNA topoisomerase 1.